KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Common Equity: 2009-2025

Historic Common Equity for Ionis Pharmaceuticals (IONS) over the last 16 years, with Sep 2025 value amounting to $618.0 million.

  • Ionis Pharmaceuticals' Common Equity fell 6.72% to $618.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $618.0 million, marking a year-over-year decrease of 6.72%. This contributed to the annual value of $588.4 million for FY2024, which is 52.15% up from last year.
  • Ionis Pharmaceuticals' Common Equity amounted to $618.0 million in Q3 2025, which was down 2.18% from $631.7 million recorded in Q2 2025.
  • Ionis Pharmaceuticals' 5-year Common Equity high stood at $771.7 million for Q4 2021, and its period low was $263.7 million during Q2 2024.
  • Over the past 3 years, Ionis Pharmaceuticals' median Common Equity value was $475.7 million (recorded in 2025), while the average stood at $468.5 million.
  • Per our database at Business Quant, Ionis Pharmaceuticals' Common Equity slumped by 66.97% in 2021 and then soared by 139.56% in 2025.
  • Quarterly analysis of 5 years shows Ionis Pharmaceuticals' Common Equity stood at $771.7 million in 2021, then declined by 25.77% to $572.9 million in 2022, then tumbled by 32.50% to $386.7 million in 2023, then surged by 52.15% to $588.4 million in 2024, then declined by 6.72% to $618.0 million in 2025.
  • Its last three reported values are $618.0 million in Q3 2025, $631.7 million for Q2 2025, and $475.7 million during Q1 2025.